software version 9.3 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
software version 9.3
Software Version 9.3, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statistical+program+statxact/software+version+9+4/pm33858718-89-13-11
Average 90 stars, based on 1 article reviews
Software Version 9.3, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statistical+program+statxact/software+version+9+4/pm33858718-89-13-11
Average 90 stars, based on 1 article reviews
software version 9.3 - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Vaccines:Article Title: A population-based estimation of breast cancer recurrence in northeast Italy with administrative healthcare databases Article Snippet: All analyses were carried out using the Article Title: Outpatient orthopaedic trauma surgery: is it safe? Article Snippet: Descriptive statistics were used to characterize our patient population regarding demographics, original mechanism of injury, OTA/AO fracture classification, and operative characteristics, using Article Title: U.S. adults with diagnosed diabetes enrolled in Medicare by age and insurance type Article Snippet: Article Title: Evaluating health-related quality of life and health resource utilization among Gabapentinoid users with substance use disorder in the US: Trends, co-prescriptions, and cost analysis Article Snippet: All analyses were performed using Article Title: Effects of Pistachio Consumption on Inflammatory Markers and Lean Body Mass in Recreationally Active Women and Men Article Snippet: Randomization allocation tables will be created by a biostatistician not involved in the clinical trial using Article Title: Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. Article Snippet: All analyses were performed via Article Title: Initial surgery versus conservative management of chronic severe aortic regurgitation in mild symptomatic older patients Article Snippet: All statistical analyses were performed using Article Title: Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. Article Snippet: Randomization of eligible participants to vaccines was conducted by an independent statistician using Software:Article Title: A population-based estimation of breast cancer recurrence in northeast Italy with administrative healthcare databases Article Snippet: All analyses were carried out using the Article Title: Outpatient orthopaedic trauma surgery: is it safe? Article Snippet: Descriptive statistics were used to characterize our patient population regarding demographics, original mechanism of injury, OTA/AO fracture classification, and operative characteristics, using Article Title: U.S. adults with diagnosed diabetes enrolled in Medicare by age and insurance type Article Snippet: Article Title: Evaluating health-related quality of life and health resource utilization among Gabapentinoid users with substance use disorder in the US: Trends, co-prescriptions, and cost analysis Article Snippet: All analyses were performed using Article Title: Effects of Pistachio Consumption on Inflammatory Markers and Lean Body Mass in Recreationally Active Women and Men Article Snippet: Randomization allocation tables will be created by a biostatistician not involved in the clinical trial using Article Title: Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. Article Snippet: All analyses were performed via Article Title: Initial surgery versus conservative management of chronic severe aortic regurgitation in mild symptomatic older patients Article Snippet: All statistical analyses were performed using Article Title: Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. Article Snippet: Randomization of eligible participants to vaccines was conducted by an independent statistician using Blocking Assay:Article Title: A population-based estimation of breast cancer recurrence in northeast Italy with administrative healthcare databases Article Snippet: All analyses were carried out using the Article Title: Outpatient orthopaedic trauma surgery: is it safe? Article Snippet: Descriptive statistics were used to characterize our patient population regarding demographics, original mechanism of injury, OTA/AO fracture classification, and operative characteristics, using Article Title: U.S. adults with diagnosed diabetes enrolled in Medicare by age and insurance type Article Snippet: Article Title: Evaluating health-related quality of life and health resource utilization among Gabapentinoid users with substance use disorder in the US: Trends, co-prescriptions, and cost analysis Article Snippet: All analyses were performed using Article Title: Effects of Pistachio Consumption on Inflammatory Markers and Lean Body Mass in Recreationally Active Women and Men Article Snippet: Randomization allocation tables will be created by a biostatistician not involved in the clinical trial using Article Title: Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. Article Snippet: All analyses were performed via Article Title: Initial surgery versus conservative management of chronic severe aortic regurgitation in mild symptomatic older patients Article Snippet: All statistical analyses were performed using Article Title: Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. Article Snippet: Randomization of eligible participants to vaccines was conducted by an independent statistician using |